Search Clinical Trials in the European Union
Duration
≤5 visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
241-260 of 525 trials
Heart Attack>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesCardiologyInternal Medicine
Acute Pulmonary Embolism>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesCardiologyPulmonology
Bile Acid Diarrhoea≤3 monthsEfficacy phase (II)≤5 visitsInvestigational MedicinesGastroenterologyInternal Medicine
Transcatheter Aortic Valve Replacement (TAVR)>2 yearsConfirmation phase (III)≤5 visitsStandard MedicinesPartially RemoteCardiologyInternal Medicine
Bartonellosis≤3 monthsConfirmation phase (III)≤5 visitsStandard MedicinesInfectious DiseasesInternal Medicine
InsomniaClimacteric Symptoms3-6 monthsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteGynecology and ObstetricsPsychiatry
Metastatic Colorectal Cancer>2 yearsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncology
Neurological Disorders≤3 monthsEfficacy phase (II)≤5 visitsStandard MedicinesCost ReimbursementNeurology
Early Stage Chronic Kidney Disease6-12 monthsMonitoring phase (IV)≤5 visitsStandard MedicinesEndocrinologyNephrology
Progressive Multiple Sclerosis>2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesNeurology
Advanced Non-Small Cell Lung Cancer (NSCLC)1-2 yearsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesPartially RemoteOncologyPulmonology
Low Back Pain≤3 monthsMonitoring phase (IV)≤5 visitsInvestigational MedicinesInternal MedicineOrthopedics and Traumatology
Primary Central Nervous System Lymphoma (PCNSL)>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesHematologyOncology
Colorectal CancerHepatocellular CarcinomaBiliary Tract Cancer>2 yearsSafety phase (I)Efficacy phase (II)≤5 visitsInvestigational MedicinesOncology
Brain MetastasesHigh-Grade Glioma>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteNeurologyOncology
Unresectable Pancreatic Cancer>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteOncology
Primary Liver Cancer>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesCost ReimbursementHepatologyInternal Medicine
Autosomal Dominant Polycystic Kidney Disease (ADPKD)Chronic Kidney Disease>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesCost ReimbursementInternal MedicineNephrology
Resectable Colon Cancer≤3 monthsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesGastroenterologyOncology